166 related articles for article (PubMed ID: 31255479)
1. Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator: ANZACS-QI 24.
Kasargod C; Devlin G; Lee M; White HD; Kerr AJ
Heart Lung Circ; 2020 Jun; 29(6):824-834. PubMed ID: 31255479
[TBL] [Abstract][Full Text] [Related]
2. Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34).
Chan D; Doughty RN; Lund M; Lee M; Kerr AJ
Heart Lung Circ; 2020 Sep; 29(9):1386-1396. PubMed ID: 32423781
[TBL] [Abstract][Full Text] [Related]
3. Heart failure clinics improve use of evidence-based heart failure therapies in patients with reduced ejection fraction following acute coronary syndrome (ANZACS-QI 48).
Chan D; Doughty RN; Mazengarb J; McLachlan A; Kerr AJ
N Z Med J; 2020 Jun; 133(1516):58-71. PubMed ID: 32525862
[TBL] [Abstract][Full Text] [Related]
4. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction.
Raposeiras-Roubín S; Abu-Assi E; Cespón-Fernández M; Ibáñez B; García-Ruiz JM; D'Ascenzo F; Simao Henriques JP; Saucedo J; Caneiro-Queija B; Cobas-Paz R; Muñoz-Pousa I; Wilton SB; González Juanatey JR; Kikkert WJ; Núñez-Gil I; Ariza-Solé A; Song X; Alexopoulos D; Liebetrau C; Kawaji T; Gaita F; Huczek Z; Nie SP; Yan Y; Fujii T; Correia L; Kawashiri MA; Kedev S; Southern D; Alfonso E; Terol B; Garay A; Zhang D; Chen Y; Xanthopoulou I; Osman N; Möllmann H; Shiomi H; Giordana F; Kowara M; Filipiak K; Wang X; Fan JY; Ikari Y; Nakahayshi T; Sakata K; Yamagishi M; Kalpak O; Íñiguez-Romo A
Rev Esp Cardiol (Engl Ed); 2020 Feb; 73(2):114-122. PubMed ID: 31105064
[TBL] [Abstract][Full Text] [Related]
5. Incidence and type of bleeding complications early and late after acute coronary syndrome admission in a New Zealand cohort (ANZACS-QI-7).
Voss WB; Lee M; Devlin GP; Kerr AJ
N Z Med J; 2016 Jul; 129(1437):27-38. PubMed ID: 27362596
[TBL] [Abstract][Full Text] [Related]
6. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
[TBL] [Abstract][Full Text] [Related]
7. Optimizing prevention and guideline-concordant care in Montenegro.
Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
[TBL] [Abstract][Full Text] [Related]
8. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge.
Hassan Y; Kassab Y; Abd Aziz N; Akram H; Ismail O
J Clin Pharm Ther; 2013 Apr; 38(2):97-100. PubMed ID: 23441979
[TBL] [Abstract][Full Text] [Related]
9. Acute coronary syndromes: clinical characteristics, management, and outcomes at the American University of Beirut Medical Center, 2002-2005.
Abdallah M; Karrowni W; Shamseddeen W; Itani S; Kobeissi L; Ghazzal Z; Alam S; Dakik HA
Clin Cardiol; 2010 Jan; 33(1):E6-E13. PubMed ID: 20014175
[TBL] [Abstract][Full Text] [Related]
10. Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry.
Al-Zakwani I; Zubaid M; Alsheikh-Ali AA; Almahmeed W; Rashed W
Cardiovasc Ther; 2018 Dec; 36(6):e12463. PubMed ID: 30079461
[TBL] [Abstract][Full Text] [Related]
11. Optimal Medical Therapy in Patients with Malignancy Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: a BleeMACS Sub-Study.
Iannaccone M; D Ascenzo F; De Filippo O; Gagliardi M; Southern DA; Raposeiras-Roubín S; Abu-Assi E; Henriques JPS; Saucedo J; González-Juanatey JR; Wilton SB; Kikkert WJ; Nuñez-Gil I; Ariza-Sole A; Song X; Alexopoulos D; Liebetrau C; Kawaji T; Huczek Z; Nie SP; Fujii T; Correia L; Kawashiri MA; García-Acuña JM; Alfonso E; Terol B; Garay A; Zhang D; Chen Y; Xanthopoulou I; Osman N; Möllmann H; Shiomi H; Kowara M; Filipiak K; Wang X; Yan Y; Fan JY; Ikari Y; Nakahashi T; Sakata K; Yamagishi M; Moretti C; Gaita F; Kalpak O; Kedev S
Am J Cardiovasc Drugs; 2017 Feb; 17(1):61-71. PubMed ID: 27738920
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome.
Hao Y; Liu J; Liu J; Smith SC; Huo Y; Fonarow GC; Ma C; Ge J; Taubert KA; Morgan L; Guo Y; Zhang Q; Wang W; Zhao D;
Am Heart J; 2016 Sep; 179():107-15. PubMed ID: 27595685
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of mid-range ejection fraction following acute coronary syndrome (ANZACS-QI 23).
Chan D; Doughty RN; Lund M; Lee M; Poppe K; Kerr AJ
N Z Med J; 2021 Jan; 134(1528):57-78. PubMed ID: 33444307
[TBL] [Abstract][Full Text] [Related]
14. [Impact of different intervention models on adherence to secondary prevention therapies in patients with acute coronary syndrome].
Liu J; Wang W; Liu J; Wang Y; Qi Y; Sun JY; Zhao D
Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Feb; 46(2):124-130. PubMed ID: 29495236
[No Abstract] [Full Text] [Related]
15. Hospital case volume and appropriate prescriptions at hospital discharge after acute myocardial infarction: a nationwide assessment.
Schiele F; Capuano F; Loirat P; Desplanques-Leperre A; Derumeaux G; Thebaut JF; Gardel C; Grenier C
Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):50-7. PubMed ID: 23233747
[TBL] [Abstract][Full Text] [Related]
16. Predictors of adherence to composite therapy after acute coronary syndromes.
Stabile E; Franzese M; Chianese S; Alfani A; Gerardi D; Colaiori I; Annunziata M; Nappi P; Scalise M; Di Serafino L; Puzone B; Avvedimento M; Leone A; Ilardi F; Piccolo R; Franzone A; Cirillo P; Morisco C; Trimarco B; Esposito G
J Cardiovasc Med (Hagerstown); 2021 Aug; 22(8):645-651. PubMed ID: 33966020
[TBL] [Abstract][Full Text] [Related]
17. High level of capture of coronary intervention and associated acute coronary syndromes in the all New Zealand acute coronary syndrome quality improvement cardiac registry and excellent agreement with national administrative datasets (ANZACS-QI 25).
Kerr AJ; Lee M; Jiang Y; Grey C; Wells S; Williams M; Jackson R; Poppe K
N Z Med J; 2019 Mar; 132(1492):19-29. PubMed ID: 30921308
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcome of acute coronary syndrome patients admitted to Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia; A retrospective cross-sectional study.
Desta DM; Nedi T; Hailu A; Atey TM; Tsadik AG; Asgedom SW; Kasahun GG; Ayalew E
PLoS One; 2020; 15(2):e0228953. PubMed ID: 32053702
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers in Acute Coronary Syndrome and Preserved Ventricular Ejection Fraction.
Cespón-Fernández M; Raposeiras-Roubín S; Abu-Assi E; Pousa IM; Queija BC; Paz RJC; Erquicia PD; Rodríguez LMD; Rodríguez EL; Busto MC; Barbeira SF; Romo AÍ
Angiology; 2020 Nov; 71(10):886-893. PubMed ID: 32757765
[TBL] [Abstract][Full Text] [Related]
20. Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland.
Welker J; Auer R; Gencer B; Muller O; Cornuz J; Matter CM; Mach F; Windecker S; Rodondi N; Nanchen D
Swiss Med Wkly; 2016; 146():w14275. PubMed ID: 26859223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
